Top

International Urogynecology Journal

Published in:

01-12-2021 | Overactive Bladder | Review Article

The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis

Authors: Sofia Tsiapakidou, Apostolos Apostolidis, Konstantinos Pantazis, Grigoris F Grimbizis, Themistoklis Mikos

Published in: International Urogynecology Journal | Issue 12/2021

Abstract

Introduction and hypothesis

Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and other proteins are related to overactive bladder (OAB) syndrome, as their urinary concentrations are significantly different from those of the general non-OAB population. This review aims to systematically assess whether NGF, BDNF, and other urinary by-products can be used as potential biomarkers to manage women with OAB.

Methods

This was a systematic review and metanalysis that was conducted according to PRISMA guidelines. Studies were identified by electronic search of Medline, Scopus, ScienceDirect, Embase, and Cochrane Register until October 2020. The included studies investigated the correlation of OAB with NGF, BDNF, and other potential biomarkers in symptomatic women and their controls.

Results

Twelve studies (581 female OAB patients and 394 female controls) were included. Urinary NGF, NGF/Cr, BDNF/Cr, ATP/Cr, and PGE2/Cr ratios were identified as potential biomarkers in female OAB patients. Results of the meta-analysis indicated that uNGF [standard mean difference (SMD) 1.45, 95% CI 0.53–2.36], NGF/Cr ratio (SMD 1.23, 95% CI 0.67–1.78), BDNF/Cr ratio (SMD 0.78, 95% CI 0.006–1.50), and BDNF/Cr ratio (RR 0.78, 95% CI 0.006–1.50) were increased in female OAB patients compared to healthy controls, whereas no difference was found for the PGE2/Cr and ATP/Cr ratios. Current data are inadequate to assess any other potential biomarkers, such as urinary MDA, ATP, and cytokines, in the management of OAB in female patients.

Conclusions

uNGF, NGF/Cr, and BDNF/Cr ratio could be used in the assessment of female OAB patients. Further studies are needed to specify OAB urinary titer levels in OAB subgroups and healthy women and their potential as diagnostic and management tools in OAB women.

Available only for authorised users

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Wein A, et al. Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49. https://doi.org/10.1016/s0090-4295(02)02243-4.CrossRefPubMed

Haylen BT, Freeman RM, Swift SE, Cosson M, Davila GW, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS)joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) & grafts in female pelvic floor surgery. Int Urogynecol J. 2011;22:3–15. https://doi.org/10.1007/s00192-010-1324-9.CrossRefPubMed

Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):622–4. https://doi.org/10.1002/nau.22609.CrossRefPubMed

Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5(6):463–6. https://doi.org/10.1097/COH.0b013e32833ed177.CrossRefPubMedPubMedCentral

Bhide AA, Cartwright R, Khullar V, Digesu GA. Biomarkers in overactive bladder. Int Urogynecol J. 2013;24(7):1065–72. https://doi.org/10.1007/s00192-012-2027-1 Erratum in: Int Urogynecol J 2013;24(10):1775–6.CrossRefPubMed

Cruz CD. Neurotrophins in bladder function: what do we know and where do we go from here? Neurourol Urodyn. 2014;33(1):39–45. https://doi.org/10.1002/nau.22438.CrossRefPubMed

Vijaya G, Cartwright R, Derpapas A, Gallo P, Fernando R, Khullar V. Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder. Int Urogynecol J. 2013;24(9):1523–8. https://doi.org/10.1007/s00192-012-2038-y.CrossRefPubMed

Kuo HC. Potential biomarkers utilized to define and manage overactive bladder syndrome. Low Urin Tract Symptoms. 2012;4(Suppl 1):32–41. https://doi.org/10.1111/j.1757-5672.2011.00131.x.CrossRefPubMed

Antunes-Lopes, Antunes-Lopes T, Pinto R, Barros SC, Botelho F, Silva CM, et al. Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. J Urol. 2013;189(1):359–65. https://doi.org/10.1016/j.juro.2012.08.187.CrossRefPubMed

10.

Wang LW, Han XM, Chen CH, Ma Y, Hai B. Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder. Int Urol Nephrol. 2014;46(2):341–7. https://doi.org/10.1007/s11255-013-0540-x.CrossRefPubMed

11.

Ochodnický P, Cruz CD, Yoshimura N, Michel MC. Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn. 2011;30(7):1227–41. https://doi.org/10.1002/nau.21022.CrossRefPubMed

12.

Seth JH, Sahai A, Khan MS, van der Aa F, de Ridder D, Panicker JN, et al. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)? BJU Int. 2013;111(3):372–80. https://doi.org/10.1111/j.1464-410X.2012.11672.x.CrossRefPubMed

13.

Chen SF, Jiang YH, Kuo HC. Urinary biomarkers in patients with detrusor underactivity with and without bladder function recovery. Int Urol Nephrol. 2017;49(10):1763–70. https://doi.org/10.1007/s11255-017-1666-z.CrossRefPubMed

14.

Rada MP, Ciortea R, Măluţan AM, Doumouchtsis SK, Bucuri CE, Clim A, et al. The profile of urinary biomarkers in overactive bladder. Neurourol Urodyn. 2020;39(8):2305–13. https://doi.org/10.1002/nau.24487.CrossRefPubMed

15.

Ghoniem G, Faruqui N, Elmissiry M, Mahdy A, Abdelwahab H, Oommen M, Abdel-Mageed AB. Differential profile analysis of urinary cytokines in patients with overactive bladder. Int Urogynecol J. 2011 Aug;22(8):953–961. https://doi.org/10.1007/s00192-011-1401-8. Erratum in: Int Urogynecol J. 2011 Aug;22(8):1069.

16.

Chung SD, Liu HT, Lin H, Kuo HC. Elevation of serum c-reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder. Neurourol Urodyn. 2011;30(3):417–20. https://doi.org/10.1002/nau.20938.CrossRefPubMed

17.

Takagi-Matsumoto H, Ng B, Tsukimi Y, Tajimi M. Effects of NSAIDs on bladder function in normal and cystitis rats: a comparison study of aspirin, indomethacin, and ketoprofen. J Pharmacol Sci. 2004;95(4):458–65. https://doi.org/10.1254/jphs.fp0040098.CrossRefPubMed

18.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65–94. https://doi.org/10.7326/0003-4819-151-4-200908180-00136.CrossRefPubMed

19.

Viswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, McPheeters M, Santaguida PL, Shamliyan T, Singh K, Tsertsvadze A, Treadwell JR (2008) Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. 2012 Mar 8. In: Methods Guide for Effectiveness and Comparative Effectiveness Reviews [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US)

20.

Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [assessed 03 Feb 2021]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

21.

Higgins J, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. http://www.cochrane-handbook.org

22.

Shi J, Luo D, Weng H, Zeng XT, Lin L, Chu H, et al. Optimally estimating the sample standard deviation from the five-number summary. Res Synth Methods. 2020;11(5):641–54. https://doi.org/10.1002/jrsm.1429.CrossRefPubMed

23.

Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–805. https://doi.org/10.1177/0962280216669183.CrossRefPubMed

24.

Pennycuff JF, Schutte SC, Hudson CO, Karp DR, Malykhina AP, Northington GM. Urinary neurotrophic peptides in postmenopausal women with and without overactive bladder. Neurourol Urodyn. 2017;36(3):740–4. https://doi.org/10.1002/nau.23011.CrossRefPubMed

25.

Suh YS, Ko KJ, Kim TH, Lee HS, Sung HH, Cho WJ, et al. Urinary nerve growth factor as a potential biomarker of treatment outcomes in overactive bladder patients. Int Neurourol J. 2017;21(4):270–81. https://doi.org/10.5213/inj.1732794.397.CrossRefPubMedPubMedCentral

26.

Mossa AH, Cammisotto PG, Shamout S, Campeau L. Imbalance of nerve growth factor metabolism in aging women with overactive bladder syndrome. World J Urol. 2020. https://doi.org/10.1007/s00345-020-03422-6.

27.

Tian XJ, Liu C, Liu K, Tang SY. Urinary biomarkers of overactive bladder. Chin Med J. 2019;132(9):1104–6. https://doi.org/10.1097/CM9.0000000000000214.CrossRefPubMedPubMedCentral

28.

Kim SR, Moon YJ, Kim SK, Bai SW. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome. Yonsei Med J. 2015;56(1):204–11. https://doi.org/10.3349/ymj.2015.56.1.204.CrossRefPubMed

29.

Silva-Ramos M, Silva I, Oliveira O, Ferreira S, Reis MJ, Oliveira JC, et al. Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome. PLoS One. 2013;8(5):e64696. https://doi.org/10.1371/journal.pone.0064696.CrossRefPubMedPubMedCentral

30.

Cho KJ, Kim HS, Koh JS, Kim JC. Changes in urinary nerve growth factor and prostaglandin E2 in women with overactive bladder after anticholinergics. Int Urogynecol J. 2013;24(2):325–30. https://doi.org/10.1007/s00192-012-1854-4.CrossRefPubMed

31.

Liu HT, Kuo HC. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol. 2008;179(6):2270–4. https://doi.org/10.1016/j.juro.2008.01.146.CrossRefPubMed

32.

Liu HT, Chen CY, Kuo HC. Urinary nerve growth factor in women with overactive bladder syndrome. BJU Int. 2011;107(5):799–803. https://doi.org/10.1111/j.1464-410X.2010.09585.x.CrossRefPubMed

33.

Suh YS, Ko KJ, Kim TH, Lee HS, Sung HH, Cho WJ, et al. Potential biomarkers for diagnosis of overactive bladder patients: urinary nerve growth factor, prostaglandin E2, and adenosine triphosphate. Int Neurourol J. 2017;21(3):171–7. https://doi.org/10.5213/inj.1732728.364.CrossRefPubMedPubMedCentral

34.

Hegele A, Knippschild S, Frohme C, Hänze J, Olbert P, Hofmann R. Changes in prostaglandin E2 in patients with idiopathic overactive bladder syndrome after botulinum toxin type a treatment: is there a clinical benefit? BMC Urol. 2014;14:85. https://doi.org/10.1186/1471-2490-14-85.CrossRefPubMedPubMedCentral

35.

Qu HC, Yan S, Zhang XL, Zhu XW, Liu YL, Wang P. Urinary nerve growth factor levels could be a biomarker for overactive bladder symptom: a meta-analysis. Genet Mol Res. 2014;13(4):8609–19. https://doi.org/10.4238/2014.April.14.14.CrossRefPubMed

36.

Birder LA, Wolf-Johnston A, Griffiths D, Resnick NM. Role of urothelial nerve growth factor in human bladder function. Neurourol Urodyn. 2007;26(3):405–9. https://doi.org/10.1002/nau.20372.CrossRefPubMedPubMedCentral

37.

Magalhaes TF, Baracat EC, Doumouchtsis SK, Haddad JM. Biomarkers in the diagnosis and symptom assessment of patients with bladder pain syndrome: a systematic review. Int Urogynecol J. 2019;30(11):1785–94. https://doi.org/10.1007/s00192-019-04075-9.CrossRefPubMed

38.

Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50(6):1306–1314; discussion 1314-5. https://doi.org/10.1016/j.eururo.2006.09.019.

39.

Palmer MH, Wu JM, Marquez CS, Rupp B, Conover MM, Newman DK. A secret club: focus groups about women’s toileting behaviors. BMC Womens Health. 2019 Mar 7;19(1):44. https://doi.org/10.1186/s12905-019-0740-3.CrossRefPubMedPubMedCentral

40.

Ke QS, Lee CL, Kuo HC. Recurrent urinary tract infection in women and overactive bladder - is there a relationship? Tzu Chi Med J. 2020;33(1):13–21. https://doi.org/10.4103/tcmj.tcmj_38_20.CrossRefPubMedPubMedCentral

41.

de Boer TA, Salvatore S, Cardozo L, Chapple C, Kelleher C, van Kerrebroeck P, et al. Pelvic organ prolapse and overactive bladder. Neurourol Urodyn. 2010;29(1):30–9. https://doi.org/10.1002/nau.20858.CrossRefPubMed

42.

Antunes-Lopes T, Carvalho-Barros S, Cruz CD, Cruz F, Martins-Silva C. Biomarkers in overactive bladder: a new objective and noninvasive tool? Adv Urol. 2011;2011:382431. https://doi.org/10.1155/2011/382431.CrossRefPubMedPubMedCentral

43.

Cheng Y, Mansfield KJ, Allen W, Chess-Williams R, Burcher E, Moore KH. ATP during early bladder stretch is important for urgency in detrusor overactivity patients. Biomed Res Int. 2014;2014:204604. https://doi.org/10.1155/2014/204604.CrossRefPubMedPubMedCentral

44.

Birder L, Andersson KE. Urothelial signaling. Physiol Rev. 2013;93(2):653–80. https://doi.org/10.1152/physrev.00030.2012.CrossRefPubMedPubMedCentral

45.

Malerba F, Paoletti F, Cattaneo A. NGF and proNGF reciprocal interference in immunoassays: open questions, criticalities, and ways forward. Front Mol Neurosci. 2016;9:63. https://doi.org/10.3389/fnmol.2016.00063.CrossRefPubMedPubMedCentral

46.

Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-a injection. Eur Urol. 2009;56(4):700–6. https://doi.org/10.1016/j.eururo.2008.04.037.CrossRefPubMed

47.

Telli O, Samancı C, Sarıcı H, Hascicek AM, Kabar M, Eroglu M. Can urinary nerve growth factor and bladder wall thickness correlation in children have a potential role to predict the outcome of non-monosymptomatic nocturnal enuresis? J Pediatr Urol. 2015 Oct;11(5):265.e1–5. https://doi.org/10.1016/j.jpurol.2015.03.018.CrossRef

48.

Yamauchi H, Akino H, Ito H, Aoki Y, Nomura T, Yokoyama O. Urinary prostaglandin E₂ was increased in patients with suprapontine brain diseases, and associated with overactive bladder syndrome. Urology. 2010 Nov;76(5):1267.e13–9. https://doi.org/10.1016/j.urology.2010.06.012.CrossRef

49.

Eapen RS, Radomski SB. Gender differences in overactive bladder. Can J Urol. 2016;23(Suppl 1):2–9.PubMed

Title: The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis
Authors: Sofia Tsiapakidou
Apostolos Apostolidis
Konstantinos Pantazis
Grigoris F Grimbizis
Themistoklis Mikos
Publication date: 01-12-2021
Publisher: Springer International Publishing
Keywords: Overactive Bladder
Biomarkers
Published in: International Urogynecology Journal / Issue 12/2021
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-021-04945-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2021

How we do an anterior sacrospinous ligament fixation for vaginal vault prolapse

Validity and reliability of two Danish versions of the ICIQ-UI SF

Laparoscopic removal of intravesically inserted transobturator tape

Translation and validation of the Polish version of the Pelvic Floor Impact Questionnaire short form 7

Outcomes collected in female pelvic floor surgical procedure registries and databases: a scoping review

Validation and cultural translation for the Brazilian Portuguese version of the Questionnaire for Urinary Incontinence Diagnosis